Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Trial Profile

Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Cobimetinib; Paclitaxel; Vemurafenib
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Aug 2017 Planned End Date changed from 1 Sep 2023 to 1 Jul 2023.
    • 04 Aug 2017 Planned primary completion date changed from 1 Sep 2023 to 1 Jul 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top